Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta.

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Polish medical diagnostics company Diagnostyka on Friday said it priced its initial public offer at 105 zlotys per share, the ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Novartis, a global leader in breast cancer care, today announced the launch of the "Your Attention, Please" campaign, which ...